Tandem Diabetes details venture-backed $123M IPO

November 5, 2013 by Arezu Sarvestani

California's Tandem Diabetes plans to offer more than 8.2 million shares of stock at a maximum of $15 apiece for an initial public offering of up to $123.2 million.

Tandem Diabetes details venture-backed $123M IPO

Tandem Diabetes Care upped the ante on its venture-backed initial public offering, increasing its maximum aggregate price to $123.2 million and pricing shares at between $13-$15 apiece.

The company, maker of the touch-screen t:slim insulin delivery system, will begin trading on the Nasdaq exchange under the ticker 'TNDM' following the IPO.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.